Research progress on biologics and therapeutic drug monitoring in pediatric inflammatory bowel disease
10.7499/j.issn.1008-8830.2504199
- VernacularTitle:生物制剂与治疗药物监测在儿童炎症性肠病中的研究进展
- Author:
Ting-Ting PAN
1
;
Hong-Lan YANG
;
Shi-Hai ZHOU
;
Hui SUN
Author Information
1. 贵州医科大学附属医院儿科,贵州 贵阳 550004
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Biologics;
Anti-tumor necrosis factor-α;
Therapeutic drug monitoring;
Individualized therapy;
Child
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(12):1556-1562
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of pediatric inflammatory bowel disease(IBD)is rising,with an especially high proportion of early-onset cases in Asia.Conventional treatments such as glucocorticoids and immunosuppressants have limited efficacy and notable adverse effects,whereas biologic therapies substantially improve remission rates and quality of life.Therapeutic drug monitoring(TDM),by assessing trough concentrations and anti-drug antibodies,enables individualized dose optimization,reduces immunogenicity,and prolongs treatment persistence.However,challenges remain,including insufficient standardization and the lack of pediatric-specific concentration thresholds.This review summarizes recent advances in biologics and TDM in pediatric IBD to inform precision treatment.
